These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

434 related items for PubMed ID: 18639952

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Cost effectiveness of adding 7-valent pneumococcal conjugate (PCV-7) vaccine to the Norwegian childhood vaccination program.
    Wisløff T, Abrahamsen TG, Bergsaker MA, Løvoll Ø, Møller P, Pedersen MK, Kristiansen IS.
    Vaccine; 2006 Jul 17; 24(29-30):5690-9. PubMed ID: 16735083
    [Abstract] [Full Text] [Related]

  • 5. Cost-effectiveness analysis of pneumococcal conjugate vaccination in England and Wales.
    Melegaro A, Edmunds WJ.
    Vaccine; 2004 Oct 22; 22(31-32):4203-14. PubMed ID: 15474710
    [Abstract] [Full Text] [Related]

  • 6. Cost-effectiveness analysis of the 10- and 13-valent pneumococcal conjugate vaccines in Argentina.
    Urueña A, Pippo T, Betelu MS, Virgilio F, Giglio N, Gentile A, Jimenez SG, Jáuregui B, Clark AD, Diosque M, Vizzotti C.
    Vaccine; 2011 Jul 12; 29(31):4963-72. PubMed ID: 21621575
    [Abstract] [Full Text] [Related]

  • 7. Cost-benefit and cost-effectiveness of the incorporation of the pneumococcal 7-valent conjugated vaccine in the routine vaccination schedule of Catalonia (Spain).
    Navas E, Salleras L, Gisbert R, Domínguez A, Timoner E, Ibáñez D, Prat A.
    Vaccine; 2005 Mar 18; 23(17-18):2342-8. PubMed ID: 15755625
    [Abstract] [Full Text] [Related]

  • 8. Economics of an adolescent meningococcal conjugate vaccination catch-up campaign in the United States.
    Ortega-Sanchez IR, Meltzer MI, Shepard C, Zell E, Messonnier ML, Bilukha O, Zhang X, Stephens DS, Messonnier NE, Active Bacterial Core Surveillance Team.
    Clin Infect Dis; 2008 Jan 01; 46(1):1-13. PubMed ID: 18171206
    [Abstract] [Full Text] [Related]

  • 9. Cost-effectiveness of vaccinating for invasive pneumococcal disease in the elderly in the Lazio region of Italy.
    Merito M, Giorgi Rossi P, Mantovani J, Curtale F, Borgia P, Guasticchi G.
    Vaccine; 2007 Jan 05; 25(3):458-65. PubMed ID: 17049685
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Cost-effectiveness analysis of a universal vaccination programme with the 7-valent pneumococcal conjugate vaccine (PCV-7) in Sweden.
    Bergman A, Hjelmgren J, Ortqvist A, Wisløff T, Kristiansen IS, Högberg LD, Persson KM, Persson U.
    Scand J Infect Dis; 2008 Jan 05; 40(9):721-9. PubMed ID: 18712627
    [Abstract] [Full Text] [Related]

  • 12. Cost-effectiveness of the CRM-based 7-valent pneumococcal conjugated vaccine (PCV7) in Argentina.
    Giglio ND, Cane AD, Micone P, Gentile A.
    Vaccine; 2010 Mar 08; 28(11):2302-10. PubMed ID: 20064478
    [Abstract] [Full Text] [Related]

  • 13. The cost-effectiveness of introducing hepatitis B vaccine into infant immunization services in Mozambique.
    Griffiths UK, Hutton G, Das Dores Pascoal E.
    Health Policy Plan; 2005 Jan 08; 20(1):50-9. PubMed ID: 15689430
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. New vaccines against otitis media: projected benefits and cost-effectiveness.
    O'Brien MA, Prosser LA, Paradise JL, Ray GT, Kulldorff M, Kurs-Lasky M, Hinrichsen VL, Mehta J, Colborn DK, Lieu TA.
    Pediatrics; 2009 Jun 08; 123(6):1452-63. PubMed ID: 19482754
    [Abstract] [Full Text] [Related]

  • 16. Cost-effectiveness of heptavalent conjugate pneumococcal vaccine (Prevenar) in Germany: considering a high-risk population and herd immunity effects.
    Lloyd A, Patel N, Scott DA, Runge C, Claes C, Rose M.
    Eur J Health Econ; 2008 Feb 08; 9(1):7-15. PubMed ID: 17333089
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Cost-effectiveness of pneumococcal conjugate vaccination in Croatia.
    Vučina VV, Filipović SK, Kožnjak N, Stamenić V, Clark AD, Mounaud B, Blau J, Hoestlandt C, Kaić B.
    Vaccine; 2015 May 07; 33 Suppl 1():A209-18. PubMed ID: 25919163
    [Abstract] [Full Text] [Related]

  • 19. Cost effectiveness of pneumococcal vaccination among Dutch infants: economic analysis of the seven valent pneumococcal conjugated vaccine and forecast for the 10 valent and 13 valent vaccines.
    Rozenbaum MH, Sanders EA, van Hoek AJ, Jansen AG, van der Ende A, van den Dobbelsteen G, Rodenburg GD, Hak E, Postma MJ.
    BMJ; 2010 Jun 02; 340():c2509. PubMed ID: 20519267
    [Abstract] [Full Text] [Related]

  • 20. A pharmacoeconomic evaluation of 7-valent pneumococcal conjugate vaccine in Canada.
    Lebel MH, Kellner JD, Ford-Jones EL, Hvidsten K, Wang EC, Ciuryla V, Arikian S, Casciano R.
    Clin Infect Dis; 2003 Feb 01; 36(3):259-68. PubMed ID: 12539065
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.